RAGE

Leading healthcare fund manager RA Capital launches biotech ETFs

Retrieved on: 
Monday, April 1, 2024
Algorithm, RAPP, Machine, Patient, Reddit, Child, ETF, CIO, Finger, Congress, General counsel, Poop, Rage, Lawyer, OOP, Nose, Machine learning, Exchange-traded fund, San Jose Sharks, Associate, Bias, POOP, IPO, MD, Insurance, VIXX, Venture, Fed, LP, RAGE, Attention, CFO, Hope, Global catastrophic risk, Opposite Day, Opposite, Institute of Management Accountants, Probability, Medicine

The first ETF that RA Capital will begin trading today is RABB (RA Best Biotech ETF).

Key Points: 
  • The first ETF that RA Capital will begin trading today is RABB (RA Best Biotech ETF).
  • This fund is composed of what RA Capital has termed "core" development-stage biotech companies held by at least one biotech specialist peer fund.
  • "What's long been missing from the menu of biotech ETFs is a fund constructed strictly based on borrowed conviction," said Peter Kolchinsky, a virologist and Managing Partner of the firm.
  • For those who think that specialists have it wrong, RA Capital is also launching the RA Peripheral Portfolio, which will trade under the symbol RAPP.

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Retrieved on: 
Thursday, February 22, 2024
Glioblastoma, RAGE, Breast cancer, BIO, Pneumonia, Conference, Patient, Cancer, Pharmaceutical industry

WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.

Key Points: 
  • WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
  • During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE).
  • Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia.

Rockstar Games Co-Founder Jamie King Joins Portal Advisory Board

Retrieved on: 
Wednesday, December 6, 2023
Red Dead Revolver, King, BAFTA, Ecosystem, Culture, Rock Star, Blockchain, Rockstar Games, RAGE, Pedigree, Publishing, Video game, Gathering of Developers, Video, IP, Web 2.0, Negotiation, Grand Theft Auto, Face, Developer

LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Portal Foundation, the leader in web2+web3 hybrid gaming that enables seamless integration between games on any blockchain, today announced that Jamie King, co-founder of Rockstar Games, has joined its advisory board. 

Key Points: 
  • At Rockstar Games, King successfully evangelized the company vision and culture globally, leading product development across a matrix of 1000 team members, directly contributing to increased shareholder value and raising the company’s valuation to $2 Billion.
  • King oversaw all studio acquisitions, software development, and cinematic production of best-selling video games, including Grand Theft Auto, Max Payne, Bully, Warriors, and Red Dead Revolver.
  • “Jamie is of course a heavyweight in the business and will create immediate strategic value across multiple fronts for Portal,” he added.
  • “This is an exciting moment for Portal as well as me personally,” said Jamie King.

Galactica Pharmaceuticals Announces the Online Publication of Newest COVID-19 Data at bioRxiv

Retrieved on: 
Wednesday, October 11, 2023
Health, Diabetes, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Viral load, BioRxiv, Symptoms of COVID-19, EUA, COVID, Therapy, Survival, RAGE, Medication, SARS-CoV-2, ICU, Golden hamster, Ventilation, Patient, Pharmaceutical industry, Vaccine

Galactica Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel fusion protein molecules, announced today the online publication of its recent COVID-19 in vivo animal data at bioRxiv.

Key Points: 
  • Galactica Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel fusion protein molecules, announced today the online publication of its recent COVID-19 in vivo animal data at bioRxiv.
  • We look forward to advancing our RAGE investigational drug into a Phase I/II COVID clinical trial in the coming months.
  • ”Millions of recovered COVID patients are still experiencing long- term COVID symptoms, often for many months post-recovery.
  • If that endpoint is met, Galactica expects to seek Emergency Use Authorization (EUA) from the United States Food and Drug Administration to quickly make the drug available to hospitalized COVID-19 patients.

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, European Respiratory Society, RAGE, Asthma, International, Serum, Gastric lavage, TSLP, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Lung, ERS, MUC5AC, Arrowhead Pharmaceuticals, Patient, MMP7, BALF, RNA interference, International Congress on Tuberculosis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.
  • Reduction of serum sRAGE was similar in healthy volunteers and in patients with asthma at the 44 mg dose level.
  • Based on interim blinded safety results from the ongoing study, ARO-RAGE has been well-tolerated to date in healthy volunteers and asthma patients.
  • “Today we announced additional data on multiple programs from our emerging pipeline of first-in-class pulmonary targeted RNAi therapeutic candidates at the European Respiratory Society International Congress.

City of Hope researchers identify biomarkers that may detect risk of advance prostate cancer in Black men

Retrieved on: 
Tuesday, August 15, 2023
Heart, DNA, Factorization of polynomials, Disease, RAGE, Biochemistry, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Diabetes, Metabolism, Genetics, AGER, Protein, EA, Clinical trial, Cancer, Research, National Institute on Minority Health and Health Disparities, Biomarker, RNA, Cell, Mass spectrometry, Genome, GLO1, Trial of the century, ELISA, Blood, Molecular medicine, Incidence, City, American Chemical Society, MG, ACS, Risk, Prostate cancer, Advanced glycation end-product, PCA, Mortality, American Cancer Society, Pharmaceutical industry, Dietary supplement, Vaccine, Black

LOS ANGELES, Aug. 15, 2023 /PRNewswire/ -- Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases. The research will be highlighted in the press program for the American Chemical Society (ACS) Fall 2023, a hybrid meeting that will be held virtually and in person in San Francisco from Aug. 13 to 17.

Key Points: 
  • Black men are more than twice as likely than other men to die from prostate cancer.
  • City of Hope leads the nation in having the first research department focused on the intersection between cancer and diabetes.
  • Shuck is an assistant professor in the Arthur Riggs Diabetes & Metabolism Institute and Department of Diabetes & Cancer Metabolism at City of Hope.
  • City of Hope researchers intend to gain a better understanding of prostate cancer disparities in the hopes of developing a diagnostic test.

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023
Insulin, RAGE, Research and development, VTV, G&A, Expense, Administration, R, FDA, General Administration of Sport of China, Therapy, Breakthrough, Pharmaceutical industry

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2023, was $5.6 million or $0.07 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $3.2 million or $0.04 per basic share.

SPEARMINT RHINO PITTSBURGH PRESENTS "STEEL CITY CAGE RAGE": A FUSION OF INTENSE, IN-YOUR-FACE ACTION & UNBRIDLED FUN!

Retrieved on: 
Thursday, July 6, 2023
Midnight, Music, RAGE, Senior, Exhibition, DJ, MARK, Playhouse, Opening Night, PORTIA, Admission, Personality, VIP, Nightclub

PITTSBURGH, July 6, 2023 /PRNewswire/ -- Spearmint Rhino, the world leader in premier live adult entertainment, is thrilled to announce the arrival of "STEEL CITY CAGE RAGE" - an ELECTRIFYING, full-contact girl fights and party experience at Spearmint Rhino Pittsburgh. Taking place on the last Saturday of every month, this event promises non-stop action and excitement.

Key Points: 
  • PITTSBURGH, July 6, 2023 /PRNewswire/ -- Spearmint Rhino, the world leader in premier live adult entertainment, is thrilled to announce the arrival of "STEEL CITY CAGE RAGE" - an ELECTRIFYING, full-contact girl fights and party experience at Spearmint Rhino Pittsburgh.
  • Taking place on the last Saturday of every month, this event promises non-stop action and excitement.
  • The grand opening night of "STEEL CITY CAGE RAGE" will be held on Saturday, July 29th, 2023, featuring three electrifying bouts at 10pm, 11pm, and Midnight.
  • Adding to the allure, the bodacious Round Card Girls, Spearmint Rhino's finest VIP dancers, will grace the event.

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Retrieved on: 
Friday, June 16, 2023
Insulin, RAGE, Diabetes, Receptor (biochemistry), Georgetown, VTV, Cancer, Dementia, Georgetown University, RAGE (receptor), Therapy, Safety, Pharmaceutical industry

Azeliragon, a small molecule receptor for advanced glycation end products (RAGE) inhibitor, was originally discovered by vTv and studied as a potential treatment for Alzheimer’s disease.

Key Points: 
  • Azeliragon, a small molecule receptor for advanced glycation end products (RAGE) inhibitor, was originally discovered by vTv and studied as a potential treatment for Alzheimer’s disease.
  • Prior to licensing azeliragon to Cantex, vTv produced a substantial body of clinical data supporting the safety and tolerability of azeliragon, as well as preclinical data demonstrating the potential therapeutic benefit of vTv’s RAGE antagonists on several diseases, including cancer and diabetic complications.
  • “We once again extend our congratulations to our partners at Cantex on the continued strengthening of their IP estate for azeliragon.
  • “We look forward to the results of Cantex's collaboration with Georgetown, which will provide greater visibility into the potential of azeliragon to alleviate cognitive decline caused by chemotherapy.”

Community-Driven Rage Coin ($RAGE) Sets a New Standard for Uselessness, Promising Simplicity and Zero Taxes

Retrieved on: 
Monday, May 29, 2023
Rage, RAGE, ETH, Tax, Movement, BSC, LP, CeX (company), Safety, Cryptocurrency, Nightclub

Rage Coin ($RAGE) proudly announces its arrival in the world of cryptocurrencies, aiming to redefine the meaning of uselessness in the memecoin space.

Key Points: 
  • Rage Coin ($RAGE) proudly announces its arrival in the world of cryptocurrencies, aiming to redefine the meaning of uselessness in the memecoin space.
  • With its fair launch on the Binance Smart Chain (BSC), LP locked, zero taxes, and contract renounced, $RAGE aims to make memes great again.
  • Rage Coin is on a mission to make memes great again, challenging the trend of derivative coins with complicated names like ShibaCumGMElonKishuTurboPepeAssFlokiMoon Inu.
  • Rage Coin ($RAGE) is not just another memecoin; it is a movement.